“The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes As Effectively As Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models”. SKIN The Journal of Cutaneous Medicine 9, no. 6 (November 10, 2025): s629. Accessed May 25, 2026. https://skin.dermsquared.com/skin/article/view/3899.